TSH response to TRH in euthyroid, hypercholesterolemic patients treated with graded doses of dextrothyroxine

John P. Bantle, Jack H. Oppenheimer, Harold L. Schwartz, Donald B. Hunninghake, Jeffrey L. Probstfield, Russell F. Hanson

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

In an attempt to determine the minimum dose of D-Thyroxine (D-T4) which will suppress pituitary TSH response to TRH, we have treated 6 euthyroid, hypercholesterolemic patients with graded doses of D-T4. TSH response was suppressed in 3 patients with 3 mg and in the remaining 3 patients with 4 mg D-T4 administered once daily. The mean TSH suppressive dose of 3.5 mg, as determined in this study, is considerably less than the 6 mg daily dose given to patients treated with D-T4 in the Coronary Drug Project. This suggests that the adverse effects observed with D-T4 treatment in the Coronary Drug Project may have been due to mild, undetected hyperthyroidism. D-T4 treatment in our patients was not associated with an increase in heart rate or ventricular ectopic beats as determined by Holter monitoring. However, bile samples obtained at the time of TSH suppression showed a significant increase in lithogenic index. In four patients, TSH suppressive doses of D-T4 were associated with a 12% decrease in mean cholesterol and a 17% decrease in mean LDL cholesterol concentrations.

Original languageEnglish (US)
Pages (from-to)63-66
Number of pages4
JournalMetabolism
Volume30
Issue number1
DOIs
StatePublished - Jan 1 1981

Fingerprint

Dextrothyroxine
Ambulatory Electrocardiography
Ventricular Premature Complexes
Hyperthyroidism
Bile
Pharmaceutical Preparations
LDL Cholesterol
Heart Rate
Cholesterol
Therapeutics

Cite this

Bantle, J. P., Oppenheimer, J. H., Schwartz, H. L., Hunninghake, D. B., Probstfield, J. L., & Hanson, R. F. (1981). TSH response to TRH in euthyroid, hypercholesterolemic patients treated with graded doses of dextrothyroxine. Metabolism, 30(1), 63-66. https://doi.org/10.1016/0026-0495(81)90220-1

TSH response to TRH in euthyroid, hypercholesterolemic patients treated with graded doses of dextrothyroxine. / Bantle, John P.; Oppenheimer, Jack H.; Schwartz, Harold L.; Hunninghake, Donald B.; Probstfield, Jeffrey L.; Hanson, Russell F.

In: Metabolism, Vol. 30, No. 1, 01.01.1981, p. 63-66.

Research output: Contribution to journalArticle

Bantle, JP, Oppenheimer, JH, Schwartz, HL, Hunninghake, DB, Probstfield, JL & Hanson, RF 1981, 'TSH response to TRH in euthyroid, hypercholesterolemic patients treated with graded doses of dextrothyroxine', Metabolism, vol. 30, no. 1, pp. 63-66. https://doi.org/10.1016/0026-0495(81)90220-1
Bantle JP, Oppenheimer JH, Schwartz HL, Hunninghake DB, Probstfield JL, Hanson RF. TSH response to TRH in euthyroid, hypercholesterolemic patients treated with graded doses of dextrothyroxine. Metabolism. 1981 Jan 1;30(1):63-66. https://doi.org/10.1016/0026-0495(81)90220-1
Bantle, John P. ; Oppenheimer, Jack H. ; Schwartz, Harold L. ; Hunninghake, Donald B. ; Probstfield, Jeffrey L. ; Hanson, Russell F. / TSH response to TRH in euthyroid, hypercholesterolemic patients treated with graded doses of dextrothyroxine. In: Metabolism. 1981 ; Vol. 30, No. 1. pp. 63-66.
@article{37f1c502efc242b3914ce036d6777324,
title = "TSH response to TRH in euthyroid, hypercholesterolemic patients treated with graded doses of dextrothyroxine",
abstract = "In an attempt to determine the minimum dose of D-Thyroxine (D-T4) which will suppress pituitary TSH response to TRH, we have treated 6 euthyroid, hypercholesterolemic patients with graded doses of D-T4. TSH response was suppressed in 3 patients with 3 mg and in the remaining 3 patients with 4 mg D-T4 administered once daily. The mean TSH suppressive dose of 3.5 mg, as determined in this study, is considerably less than the 6 mg daily dose given to patients treated with D-T4 in the Coronary Drug Project. This suggests that the adverse effects observed with D-T4 treatment in the Coronary Drug Project may have been due to mild, undetected hyperthyroidism. D-T4 treatment in our patients was not associated with an increase in heart rate or ventricular ectopic beats as determined by Holter monitoring. However, bile samples obtained at the time of TSH suppression showed a significant increase in lithogenic index. In four patients, TSH suppressive doses of D-T4 were associated with a 12{\%} decrease in mean cholesterol and a 17{\%} decrease in mean LDL cholesterol concentrations.",
author = "Bantle, {John P.} and Oppenheimer, {Jack H.} and Schwartz, {Harold L.} and Hunninghake, {Donald B.} and Probstfield, {Jeffrey L.} and Hanson, {Russell F.}",
year = "1981",
month = "1",
day = "1",
doi = "10.1016/0026-0495(81)90220-1",
language = "English (US)",
volume = "30",
pages = "63--66",
journal = "Metabolism: Clinical and Experimental",
issn = "0026-0495",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - TSH response to TRH in euthyroid, hypercholesterolemic patients treated with graded doses of dextrothyroxine

AU - Bantle, John P.

AU - Oppenheimer, Jack H.

AU - Schwartz, Harold L.

AU - Hunninghake, Donald B.

AU - Probstfield, Jeffrey L.

AU - Hanson, Russell F.

PY - 1981/1/1

Y1 - 1981/1/1

N2 - In an attempt to determine the minimum dose of D-Thyroxine (D-T4) which will suppress pituitary TSH response to TRH, we have treated 6 euthyroid, hypercholesterolemic patients with graded doses of D-T4. TSH response was suppressed in 3 patients with 3 mg and in the remaining 3 patients with 4 mg D-T4 administered once daily. The mean TSH suppressive dose of 3.5 mg, as determined in this study, is considerably less than the 6 mg daily dose given to patients treated with D-T4 in the Coronary Drug Project. This suggests that the adverse effects observed with D-T4 treatment in the Coronary Drug Project may have been due to mild, undetected hyperthyroidism. D-T4 treatment in our patients was not associated with an increase in heart rate or ventricular ectopic beats as determined by Holter monitoring. However, bile samples obtained at the time of TSH suppression showed a significant increase in lithogenic index. In four patients, TSH suppressive doses of D-T4 were associated with a 12% decrease in mean cholesterol and a 17% decrease in mean LDL cholesterol concentrations.

AB - In an attempt to determine the minimum dose of D-Thyroxine (D-T4) which will suppress pituitary TSH response to TRH, we have treated 6 euthyroid, hypercholesterolemic patients with graded doses of D-T4. TSH response was suppressed in 3 patients with 3 mg and in the remaining 3 patients with 4 mg D-T4 administered once daily. The mean TSH suppressive dose of 3.5 mg, as determined in this study, is considerably less than the 6 mg daily dose given to patients treated with D-T4 in the Coronary Drug Project. This suggests that the adverse effects observed with D-T4 treatment in the Coronary Drug Project may have been due to mild, undetected hyperthyroidism. D-T4 treatment in our patients was not associated with an increase in heart rate or ventricular ectopic beats as determined by Holter monitoring. However, bile samples obtained at the time of TSH suppression showed a significant increase in lithogenic index. In four patients, TSH suppressive doses of D-T4 were associated with a 12% decrease in mean cholesterol and a 17% decrease in mean LDL cholesterol concentrations.

UR - http://www.scopus.com/inward/record.url?scp=0019506077&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019506077&partnerID=8YFLogxK

U2 - 10.1016/0026-0495(81)90220-1

DO - 10.1016/0026-0495(81)90220-1

M3 - Article

VL - 30

SP - 63

EP - 66

JO - Metabolism: Clinical and Experimental

JF - Metabolism: Clinical and Experimental

SN - 0026-0495

IS - 1

ER -